AbbVie’s migraine drug meets main goal of late-stage study
By Thomson ReutersJun 18, 2025 | 6:26 AM
(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage trial.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
